X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-12-19 | OLMA | Olema Pharmaceuticals, Inc. | Clark Ian T | Dir | S - Sale+OE | $29.73 | -264,800 | 0 | -100% | -$7,873,109 | |||||
2025-12-19 | OLMA | Olema Pharmaceuticals, Inc. | Myles David C. | CH. DISCOV., NON-CLIN DEV OFF | S - Sale | $30.46 | -51,000 | 710,558 | -7% | -$1,553,544 | ||||||
| DM | 2025-12-19 | OLMA | Olema Pharmaceuticals, Inc. | Zojwalla Naseem | Chief Medical Officer | S - Sale+OE | $27.94 | -269,509 | 4,488 | -98% | -$7,530,148 | |||||
2025-12-23 | AMLX | Amylyx Pharmaceuticals, Inc. | Firestone Karen | Dir | P - Purchase | $12.45 | +8,100 | 63,100 | +15% | +$100,845 | ||||||
2025-12-22 | OKUR | Onkure Therapeutics, Inc. | Saccomano Nicholas A | Pres, CEO | S - Sale | $2.97 | -87 | 7,419 | -1% | -$258 | ||||||
2025-12-22 | OKUR | Onkure Therapeutics, Inc. | Leverone Jason A. | CFO | S - Sale | $2.97 | -302 | 16,301 | -2% | -$896 | ||||||
| D | 2025-12-22 | MIRM | Mirum Pharmaceuticals, Inc. | Ramasastry Saira | Dir | S - Sale+OE | $80.00 | -5,000 | 0 | -100% | -$400,000 | |||||
| D | 2025-12-19 | MIRM | Mirum Pharmaceuticals, Inc. | Grey Michael G | Dir | S - Sale+OE | $78.00 | -50,000 | 280,160 | -15% | -$3,900,000 | |||||
2025-12-19 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S - Sale | $16.84 | -5,000 | 897,688 | -1% | -$84,206 | ||||||
2025-12-19 | ARWR | Arrowhead Pharmaceuticals, Inc. | Waddill William D. | Dir | S - Sale | $67.65 | -8,367 | 56,563 | -13% | -$566,038 | ||||||
2025-12-19 | ARWR | Arrowhead Pharmaceuticals, Inc. | Vakiener Victoria | Dir | S - Sale | $67.68 | -10,040 | 35,723 | -22% | -$679,491 | ||||||
| M | 2025-12-19 | ARWR | Arrowhead Pharmaceuticals, Inc. | Anzalone Christopher Richard | CEO | S - Sale | $68.04 | -26,031 | 3,805,926 | -1% | -$1,771,022 | |||||
2025-12-19 | ARWR | Arrowhead Pharmaceuticals, Inc. | Olukotun Adeoye Y | Dir | S - Sale | $67.66 | -10,000 | 33,600 | -23% | -$676,623 | ||||||
| D | 2025-12-19 | PTCT | Ptc Therapeutics, Inc. | Pauwels Eric | CHIEF BUSINESS OFFICER | S - Sale+OE | $77.26 | -20,508 | 70,373 | -23% | -$1,584,350 | |||||
2025-12-22 | IMNM | Immunome Inc. | Barchas Isaac | Dir | S - Sale | $21.74 | -383,200 | 4,165,824 | -8% | -$8,330,080 | ||||||
| M | 2025-12-19 | CLNN | Clene Inc. | Ugwumba Chidozie | 10% | S - Sale | $6.49 | -9,949 | 383,201 | -3% | -$64,564 | |||||
2025-12-23 | UTHR | United Therapeutics Corp | Malcolm Jan | Dir | S - Sale | $512.12 | -50 | 420 | -11% | -$25,606 | ||||||
| D | 2025-12-22 | UTHR | United Therapeutics Corp | Sullivan Louis W | Dir | S - Sale+OE | $512.14 | -5,950 | 3,200 | -65% | -$3,047,201 | |||||
2025-12-23 | ANAB | Anaptysbio, Inc | Ware J. Anthony | Dir | S - Sale | $49.58 | -3,900 | 9,630 | -29% | -$193,343 | ||||||
2025-12-19 | ALZN | Alzamend Neuro, Inc. | Horne William B. | Dir | S - Sale | $2.12 | -3,333 | 0 | -100% | -$7,059 | ||||||
| D | 2025-12-22 | ANAB | Anaptysbio, Inc | Lizzul Paul F. | Chief Medical Officer | S - Sale+OE | $50.00 | -1,500 | 26,967 | -5% | -$75,000 | |||||
| D | 2025-12-22 | ANAB | Anaptysbio, Inc | Mulroy Dennis | CFO | S - Sale+OE | $50.00 | -10,000 | 9,401 | -52% | -$500,000 | |||||
| D | 2025-12-22 | ANAB | Anaptysbio, Inc | Loumeau Eric J | GC | S - Sale+OE | $51.00 | -10,000 | 8,947 | -53% | -$510,000 | |||||
| D | 2025-12-23 | EQ | Equillium, Inc. | Zedelmayer Christine | SVP, COO | S - Sale+OE | $1.50 | -100,000 | 91,444 | -52% | -$150,000 | |||||
2025-12-19 | FOLD | Amicus Therapeutics, Inc. | Clark David Michael | Chief People Officer | S - Sale | $14.17 | -25,642 | 245,690 | -9% | -$363,380 | ||||||
| D | 2025-12-22 | CYTK | Cytokinetics Inc | Wierenga Wendell | Dir | S - Sale+OE | $66.14 | -20,000 | 32,444 | -38% | -$1,322,800 | |||||
2025-12-23 | ALT | Altimmune, Inc. | Gill John | Dir | P - Purchase | $4.10 | +12,500 | 12,500 | New | +$51,250 | ||||||
| D | 2025-12-22 | BCAX | Bicara Therapeutics Inc. | Hyep Ivan | CFO | S - Sale+OE | $18.31 | -9,200 | 145,355 | -6% | -$168,492 | |||||
| D | 2025-12-19 | XNCR | Xencor Inc | Desjarlais John R | SVP, CSO | S - Sale+OE | $15.72 | -73,367 | 242,885 | -23% | -$1,153,329 | |||||
| D | 2025-12-19 | XNCR | Xencor Inc | Dahiyat Bassil I | Pres, CEO | S - Sale+OE | $15.71 | -114,377 | 477,259 | -19% | -$1,796,863 | |||||
| D | 2025-12-22 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Chief Scientific Officer | S - Sale+OE | $2.67 | -5,673 | 0 | -100% | -$15,168 | |||||
| A | 2025-12-23 | GALT | Galectin Therapeutics Inc | Freeman Kevin D | Dir | P - Purchase | $3.55 | +5,500 | 153,332 | +4% | +$19,514 | |||||
| A | 2025-12-23 | GALT | Galectin Therapeutics Inc | Freeman Kevin D | Dir | P - Purchase | $3.55 | +5,500 | 137,269 | +4% | +$19,514 | |||||
2025-12-23 | GALT | Galectin Therapeutics Inc | Eldred Kary | Dir | P - Purchase | $3.73 | +700 | 69,807 | +1% | +$2,611 | ||||||
2025-12-23 | GALT | Galectin Therapeutics Inc | Freeman Kevin D | Dir | P - Purchase | $3.55 | +5,500 | 137,269 | +4% | +$19,514 | ||||||
2025-12-23 | GALT | Galectin Therapeutics Inc | Eldred Kary | Dir | P - Purchase | $3.73 | +700 | 69,807 | +1% | +$2,611 | ||||||
| D | 2025-12-22 | MAIA | Maia Biotechnology, Inc. | Smith Stan | Dir | P - Purchase | $1.22 | +57,189 | 1,435,218 | +4% | +$69,999 | |||||
| D | 2025-12-22 | MAIA | Maia Biotechnology, Inc. | Chaouki Steven M | Dir | P - Purchase | $1.22 | +40,849 | 151,873 | +37% | +$49,999 | |||||
| D | 2025-12-22 | MAIA | Maia Biotechnology, Inc. | Louie Ngar Yee | Dir | P - Purchase | $1.22 | +81,699 | 1,248,888 | +7% | +$100,000 | |||||
2025-12-22 | PGEN | Precigen, Inc. | Kirk Randal J | Dir, 10% | S - Sale | $4.18 | -1,900,036 | 122,046,184 | -2% | -$7,942,150 | ||||||
| M | 2025-12-18 | BNTC | Benitec Biopharma Inc. | Suvretta Capital Management, LLC | Dir, 10% | P - Purchase | $11.68 | +46,141 | 1,826,653 | +3% | +$538,972 | |||||
| D | 2025-12-22 | ZYME | Zymeworks Inc. | Galbraith Kenneth | Chair, CEO | S - Sale+OE | $27.02 | -47,528 | 133,275 | -26% | -$1,284,311 | |||||
| M | 2025-12-18 | MRUS | Merus N.V. | Genmab A/S | 10% | P - Purchase | $97.00 | +278,441 | 72,013,065 | 0% | +$27,008,777 | |||||
2025-12-18 | LITS | Lite Strategy, Inc. | Schornstein Alexander | 10% | S - Sale | $1.37 | -690,611 | 3,674,862 | -16% | -$946,137 | ||||||
2025-12-22 | ALT | Altimmune, Inc. | Durso Jerome Benedict | Dir | P - Purchase | $4.13 | +12,500 | 12,500 | New | +$51,569 | ||||||
2025-12-19 | RPRX | Royalty Pharma Plc | Urist Marshall | EVP, Research, Investments | S - Sale | $38.38 | -20,000 | 146,418 | -12% | -$767,582 | ||||||
| D | 2025-12-19 | SUPN | Supernus Pharmaceuticals, Inc. | Mottola Frank | SVP, Chief Tech. Ops. Officer | S - Sale+OE | $50.41 | -20,000 | 15,496 | -56% | -$1,008,150 | |||||
2025-12-19 | LITS | Lite Strategy, Inc. | Flynn James P | Dir | P - Purchase | $1.40 | +70,000 | 100,000 | +233% | +$97,699 | ||||||
2025-12-18 | HYPD | Hyperion Defi, Inc. | Strahlman Ellen R | Dir | P - Purchase | $3.14 | +38,444 | 170,598 | +29% | +$120,664 | ||||||
2025-12-19 | IMNM | Immunome Inc. | Siegall Clay B | Pres, CEO | P - Purchase | $20.48 | +7,278 | 660,525 | +1% | +$149,053 | ||||||
2025-12-19 | IMNM | Immunome Inc. | Tsai Philip | Chief Technical Officer | P - Purchase | $20.49 | +10,000 | 43,300 | +30% | +$204,900 | ||||||
2025-12-19 | EVMN | Evommune, Inc. | Hopfner Robert Lorne | Dir, 10% | P - Purchase | $17.35 | +1,000 | 3,372,001 | 0% | +$17,350 | ||||||
2025-12-18 | RNXT | Renovorx, Inc. | Bagai Shaun | CEO | P - Purchase | $0.90 | +5,000 | 340,040 | +1% | +$4,507 | ||||||
| D | 2025-12-18 | CRMD | Cormedix Inc. | Todisco Joseph | CEO | S - Sale+OE | $12.00 | -30,000 | 509,496 | -6% | -$360,000 | |||||
| D | 2025-12-17 | ROIV | Roivant Sciences Ltd. | Sukhatme Mayukh | Pres, CIO | S - Sale+OE | $23.09 | -26,831 | 18,836,547 | 0% | -$619,528 | |||||
2025-12-19 | TYRA | Tyra Biosciences, Inc. | More Robert J | Dir | S - Sale | $25.00 | -10,000 | 3,823,425 | 0% | -$250,000 | ||||||
| D | 2025-12-17 | MNKD | Mannkind Corp | Castagna Michael | CEO | S - Sale+OE | $6.01 | -65,804 | 2,504,792 | -3% | -$395,482 | |||||
| M | 2025-12-17 | SION | Sionna Therapeutics, Inc. | Orbimed Advisors LLC | Dir | S - Sale | $44.49 | -1,875 | 3,595,011 | 0% | -$83,428 | |||||
| M | 2025-12-17 | SION | Sionna Therapeutics, Inc. | Thompson Peter A. | Dir | S - Sale | $44.49 | -1,875 | 3,595,011 | 0% | -$83,428 | |||||
2025-12-17 | HYPD | Hyperion Defi, Inc. | Walters Happy David | Dir | P - Purchase | $3.02 | +61,930 | 111,930 | +124% | +$187,152 | ||||||
2025-12-17 | ARWR | Arrowhead Pharmaceuticals, Inc. | Anzalone Christopher Richard | CEO | S - Sale | $64.04 | -85,000 | 3,831,957 | -2% | -$5,443,462 | ||||||
| D | 2025-12-19 | ORKA | Oruka Therapeutics, Inc. | Goncalves Joana | Chief Medical Officer | S - Sale+OE | $30.61 | -7,000 | 1,518 | -82% | -$214,293 | |||||
| M | 2025-12-17 | RPRX | Royalty Pharma Plc | Lloyd George W. | EVP, Investments, CLO | S - Sale | $38.55 | -110,000 | 779,915 | -12% | -$4,240,333 | |||||
| DM | 2025-12-17 | PTCT | Ptc Therapeutics, Inc. | Pauwels Eric | CHIEF BUSINESS OFFICER | S - Sale+OE | $75.40 | -43,492 | 70,373 | -38% | -$3,279,275 | |||||
2025-12-19 | XERS | Xeris Biopharma Holdings, Inc. | Johnson John | Dir | S - Sale | $7.22 | -135,400 | 698,083 | -16% | -$977,019 | ||||||
2025-12-19 | SVRA | Savara Inc | Ramsay David A | Dir | S - Sale | $6.06 | -20,000 | 2,533,642 | -1% | -$121,220 | ||||||
2025-12-17 | ADTX | Aditxt, Inc. | Brady Brian Michael | Dir | S - Sale | $1.75 | -1 | 3 | -25% | -$2 | ||||||
2025-12-18 | ANIP | Ani Pharmaceuticals Inc | Davis Krista | SVP, CHRO | S - Sale | $82.40 | -1,622 | 58,564 | -3% | -$133,653 | ||||||
| D | 2025-12-18 | UTHR | United Therapeutics Corp | Thompson Tommy G | Dir | S - Sale+OE | $500.59 | -910 | 22,480 | -4% | -$455,533 | |||||
| DM | 2025-12-17 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $505.38 | -10,000 | 639,489 | -2% | -$5,053,778 | |||||
| D | 2025-12-18 | KURA | Kura Oncology, Inc. | Burrows Francis | Chief Scientific Officer | S - Sale+OE | $9.78 | -23,726 | 33,735 | -41% | -$231,931 | |||||
| D | 2025-12-18 | MIRM | Mirum Pharmaceuticals, Inc. | Ramasastry Saira | Dir | S - Sale+OE | $69.73 | -2,000 | 0 | -100% | -$139,460 | |||||
| D | 2025-12-18 | VTYX | Ventyx Biosciences, Inc. | Mohan Raju | CEO, Pres | S - Sale+OE | $7.72 | -47,345 | 2,372,863 | -2% | -$365,461 | |||||
| D | 2025-12-18 | VTYX | Ventyx Biosciences, Inc. | Nuss John | Chief Scientific Officer | S - Sale+OE | $7.72 | -12,675 | 489,481 | -3% | -$97,840 | |||||
| D | 2025-12-18 | INSM | Insmed Inc | Lewis William | Chair, CEO | S - Sale+OE | $166.97 | -10,699 | 588,335 | -2% | -$1,786,457 | |||||
| D | 2025-12-17 | GALT | Galectin Therapeutics Inc | Lewis Joel | Pres, CEO | S - Sale+OE | $7.06 | -7,829 | 834,592 | -1% | -$55,241 | |||||
| D | 2025-12-17 | GALT | Galectin Therapeutics Inc | Jamil Khurram | Chief Medical Officer | S - Sale+OE | $7.04 | -19,442 | 0 | -100% | -$136,872 | |||||
| D | 2025-12-18 | SUPN | Supernus Pharmaceuticals, Inc. | Bhatt Padmanabh P. | SVP of IP, CSO | S - Sale+OE | $44.44 | -710 | 14,508 | -5% | -$31,552 | |||||
2025-12-17 | SLGL | Sol-Gel Technologies Ltd. | Opaleye Management Inc. | 10% | P - Purchase | $40.37 | +2,735 | 384,530 | +1% | +$110,412 | ||||||
| D | 2025-12-17 | PVLA | Palvella Therapeutics, Inc. | Goin Kathleen | COO | S - Sale+OE | $96.47 | -4,302 | 0 | -100% | -$415,023 | |||||
| D | 2025-12-17 | GALT | Galectin Therapeutics Inc | Shlevin Harold H. | Dir | S - Sale+OE | $7.04 | -24,499 | 6,500 | -79% | -$172,424 | |||||
2025-12-18 | MNPR | Monopar Therapeutics | Klausner Arthur J | Dir | S - Sale | $67.15 | -5,121 | 8,762 | -37% | -$343,889 | ||||||
2025-12-17 | HYPD | Hyperion Defi, Inc. | Geltzeiler Michael S | Dir | P - Purchase | $3.01 | +30,000 | 88,015 | +52% | +$90,210 | ||||||
2025-12-17 | RNXT | Renovorx, Inc. | Bagai Shaun | CEO | P - Purchase | $0.85 | +5,000 | 335,040 | +2% | +$4,262 | ||||||
2025-12-18 | GLSI | Greenwich Lifesciences, Inc. | Patel Snehal | CEO, CFO, 10% | P - Purchase | $12.62 | +4,100 | 5,592,202 | 0% | +$51,742 | ||||||
2025-12-16 | SRPT | Sarepta Therapeutics, Inc. | Estepan Ian Michael | COO | S - Sale | $22.31 | -13,187 | 193,300 | -6% | -$294,202 | ||||||
| M | 2025-12-16 | ROIV | Roivant Sciences Ltd. | Gold Daniel Allen | Dir | S - Sale | $23.05 | -1,694,614 | 16,353,113 | -9% | -$39,065,213 | |||||
| M | 2025-12-16 | ROIV | Roivant Sciences Ltd. | Manchester Keith S | Dir | S - Sale | $23.05 | -1,694,614 | 16,353,113 | -9% | -$39,065,213 | |||||
| M | 2025-12-16 | ROIV | Roivant Sciences Ltd. | Qvt Financial LP | Director by Deputization | S - Sale | $23.05 | -1,694,614 | 16,353,113 | -9% | -$39,065,213 | |||||
2025-12-17 | IRON | Disc Medicine, Inc. | Bitterman Kevin | Dir | S - Sale | $91.47 | -754 | 14,013 | -5% | -$68,968 | ||||||
| D | 2025-12-18 | NRIX | Nurix Therapeutics, Inc. | Ring Christine | GC | S - Sale+OE | $17.90 | -3,760 | 50,897 | -7% | -$67,314 | |||||
| M | 2025-12-16 | MRUS | Merus N.V. | Genmab A/S | 10% | P - Purchase | $97.00 | +271,547 | 71,734,624 | 0% | +$26,340,059 | |||||
| M | 2025-12-16 | RCUS | Arcus Biosciences, Inc. | Tang Carolyn C. | GC | S - Sale | $22.01 | -14,468 | 124,734 | -10% | -$318,496 | |||||
| M | 2025-12-16 | RCUS | Arcus Biosciences, Inc. | Markus Richard | Chief Medical Officer | S - Sale | $22.01 | -9,546 | 65,647 | -13% | -$210,144 | |||||
| M | 2025-12-16 | RCUS | Arcus Biosciences, Inc. | Azoy Alexander | Chief Accounting Officer | S - Sale | $22.13 | -8,832 | 18,531 | -32% | -$195,434 | |||||
| M | 2025-12-16 | RCUS | Arcus Biosciences, Inc. | Goeltz II Robert C. | CFO | S - Sale | $22.01 | -12,662 | 74,476 | -15% | -$278,739 | |||||
| M | 2025-12-16 | RCUS | Arcus Biosciences, Inc. | Jarrett Jennifer | COO | S - Sale | $22.01 | -21,208 | 193,024 | -10% | -$466,870 | |||||
| M | 2025-12-16 | RCUS | Arcus Biosciences, Inc. | Jaen Juan C. | Pres | S - Sale | $22.01 | -21,208 | 1,300,075 | -2% | -$466,870 | |||||
| M | 2025-12-16 | RCUS | Arcus Biosciences, Inc. | Rosen Terry J | CEO | S - Sale | $22.01 | -54,691 | 2,194,809 | -2% | -$1,203,959 | |||||
| D | 2025-12-17 | AMPH | Amphastar Pharmaceuticals, Inc. | Zhou Rong | SENIOR EVP, PRODUCTION CENTER | S - Sale+OE | $26.20 | -9,787 | 242,711 | -4% | -$256,379 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |